Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Nordisk AS's Net Income Including Noncontrolling Interests for the
three
months ended in Jun. 2026 was €2,807 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2026 was €15,584 Mil.
Novo Nordisk AS Net Income Including Noncontrolling Interests Related Terms
Novo Nordisk AS Net Income Including Noncontrolling Interests Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Net Income Including Noncontrolling Interests can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Net Income Including Noncontrolling Interests Chart
Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €15,584 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income Including Noncontrolling Interests of €15,584 Mil mean?
Novo Nordisk AS (WBO:NNO2) has a Net Income Including Noncontrolling Interests of €15,584 Mil as of Jun. 2026.
Is Novo Nordisk AS's Net Income Including Noncontrolling Interests too high?
Novo Nordisk AS's current Net Income Including Noncontrolling Interests is €15,584 Mil. Overall, Novo Nordisk AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Net Income Including Noncontrolling Interests compare to LLY and JNJ?
Novo Nordisk AS's Net Income Including Noncontrolling Interests of €15,584 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income Including Noncontrolling Interests for a Drug Manufacturers company?
A good Net Income Including Noncontrolling Interests depends on the Drug Manufacturers industry context. However, Net Income Including Noncontrolling Interests should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income Including Noncontrolling Interests mean?
A high Net Income Including Noncontrolling Interests can signal that a stock is expensive relative to its fundamentals. Novo Nordisk AS's current Net Income Including Noncontrolling Interests is €15,584 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €93.42, compared to a current price of €40.96 — trading 56.2% below its estimated fair value. The current Net Income Including Noncontrolling Interests is €15,584 Mil. Novo Nordisk AS's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income Including Noncontrolling Interests calculated?
Net Income Including Noncontrolling Interests is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current Net Income Including Noncontrolling Interests is €15,584 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €40.96 is trading 56.2% below its estimated GF Value™ of €93.42.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
Net Income Including Noncontrolling Interests: €15,584 Mil
GF Value™: €93.42 vs. price of €40.96 (56.2% below fair value)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
80GF Score
Get the complete analysis for WBO:NNO2
Net Income Including Noncontrolling Interests is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 
